جميع الدراسات
مُصرحالمرحلة الأولى والمرحلة الثانية (متكاملة) - أخرىتداخلي

PHASE I/IIa CLINICAL TRIAL FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE WITH A NEW GENERATION OF MESENCHYMAL STROMAL CELLS ECTOPICALLY EXPRESSING CXCR4 AND IL-10 IN STEROID-REFRACTORY AND INTOLERANT OR RUXOLITINIB-REFRACTORY PATIENTS

Graft-versus-host disease (GvHD) is a serious complication that can happen after a stem cell or bone marrow transplant. It occurs when donor immune cells see the patient's body as foreign and attack healthy organs such as the skin, gut, or liver. Standard treatment uses steroid medicines, followed by a drug called ruxolitinib if steroids do not work. However, some people do not respond to these drugs or cannot take them. This early-stage clinical trial is testing an experimental treatment made from donor stem cells taken from fatty tissue. Scientists have gently modified these cells in a laboratory so they can travel better to inflamed areas and help calm the immune system. The main aim of the study is to check whether these cell infusions are safe, while also seeing if they can help control GvHD symptoms.

نظرة سريعة

الحالة
مُصرح
المرحلة
المرحلة الأولى والمرحلة الثانية (متكاملة) - أخرى
الراعي
Fundacion Instituto De Investigacion Sanitaria De Navarra
الهدف من التسجيل
15
ابدأ
04 Nov 2026

ما هو موضوع هذه الدراسة؟

A stem cell or bone marrow transplant can be a life-saving treatment for blood cancers and other serious conditions. However, it carries a risk of graft-versus-host disease, or GvHD. In acute GvHD, the newly transplanted immune cells from the donor begin attacking the patient's own healthy tissues. This can cause painful rashes, severe gut problems, and liver damage, often developing in the first few months after transplant.

Doctors usually treat acute GvHD with strong steroids to calm the immune system. If steroids do not work, another drug called ruxolitinib is often used. Unfortunately, for some patients, these medicines fail to control the disease, or the side effects are too severe to continue. When these standard treatments stop working, doctors have very few proven options left to protect the patient's organs.

This trial is testing a new type of cell therapy designed to step in when standard drugs have failed. The treatment uses specialised healing cells, called mesenchymal stromal cells, taken from healthy donor fat tissue. Scientists have added two natural signals (called CXCR4 and IL-10) to the cells. These signals act like a satnav and a brake: they guide the cells straight to the inflamed tissues and help switch off the damaging immune attack.

Because this is an early-stage study (Phase I/IIa), the main goal is to make sure the modified cells are safe to receive and do not cause unexpected harm. Doctors will also closely monitor patients to see if the treatment helps calm their GvHD symptoms and improves their recovery.

النقاط الرئيسية

  • Testing a new donor cell therapy for adults with acute GvHD.
  • Aimed at patients whose condition has not responded to steroids or ruxolitinib.
  • Uses lab-modified stem cells designed to calm inflammation and protect healthy tissue.
  • The primary goal is to ensure the treatment is safe and well tolerated.
  • Participation is voluntary, and you can leave the study at any time.

من قد يكون مؤهلاً؟

This study is designed for adults aged 18 and over who have developed acute graft-versus-host disease following a donor transplant.

To be considered, standard treatments must not have worked well enough. Specifically, your GvHD must not have cleared up with steroid medicines, and you must either have tried ruxolitinib without success, been unable to tolerate it, or been advised that ruxolitinib is not safe for you to take.

Because this is an early clinical trial, your medical team will also need to check your general organ health and ensure you do not have any active complications that would make taking part unsafe for you.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. عمري 18 عامًا أو أكثر.
  2. I have had a donor stem cell or bone marrow transplant.
  3. I have been diagnosed with acute graft-versus-host disease (GvHD).
  4. Steroid treatment has not controlled my GvHD.
  5. The drug ruxolitinib has not worked for me, or I am unable to take it.
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you take part, you will receive the study treatment as an infusion (a slow drip into a vein) in a hospital setting. You may receive more than one dose over a planned schedule. During and right after each infusion, the medical team will watch you very closely to make sure you do not experience any sudden reactions.

Throughout the study, you will need to attend regular clinic visits. At these visits, doctors will examine your skin, gut, and liver to see how your GvHD is responding. You will have routine blood tests and other health checks to track your safety. The study team will follow your progress over several weeks and months to record any side effects and see how long the benefits last.

المخاطر والفوائد المحتملة

The main hope of this study is that the modified cells will help calm down the immune attack and ease your GvHD symptoms when other medicines have not worked. However, because this is an early-stage trial, there is no guarantee that your health will improve. There are also risks, including reactions during the infusion, allergic responses, or unexpected side effects from the experimental cells. Your safety will be monitored continuously. Taking part is completely your choice, and you can withdraw from the trial at any point without it affecting your standard NHS care or your relationship with your medical team.

المواقع (1)

بعض مواقع الأماكن تقريبية. نحن نعمل على تحسين ذلك — يرجى التحقق مع فريق التجربة قبل السفر.
  • —
    غير مؤكد
    إسبانيا

أسئلة شائعة

What is acute graft-versus-host disease (GvHD)?

It is a condition where donor immune cells from a transplant mistakenly attack the patient's healthy body tissues, most commonly the skin, digestive system, and liver.

Where do the study cells come from?

They come from healthy donor fat tissue. In a laboratory, scientists grow and modify them so they can better target inflammation and help quieten overactive immune cells.

How is the treatment given?

The cells are given directly into your bloodstream through an intravenous (IV) drip, similar to a blood transfusion, while you are monitored in hospital.

What does Phase I/IIa mean?

This means it is an early clinical trial. The main focus is checking that the treatment is safe and finding the right dose, while also gathering early clues about how well it works.

Do I have to pay to take part?

No. Clinical trials in the UK do not charge patients for study treatments. You should speak with the research team about whether travel costs can be reimbursed.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.